Column Group LLC Trims Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Column Group LLC lowered its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 50.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,328,613 shares of the company's stock after selling 1,352,008 shares during the period. RAPT Therapeutics accounts for approximately 3.8% of Column Group LLC's portfolio, making the stock its 4th largest position. Column Group LLC owned 3.80% of RAPT Therapeutics worth $2,099,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RAPT. Barclays PLC increased its stake in shares of RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after acquiring an additional 29,195 shares in the last quarter. JPMorgan Chase & Co. increased its stake in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock valued at $34,000 after purchasing an additional 25,130 shares in the last quarter. SG Americas Securities LLC increased its stake in RAPT Therapeutics by 401.9% during the 4th quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock valued at $84,000 after purchasing an additional 42,636 shares in the last quarter. Medicxi Ventures Management Jersey Ltd bought a new stake in RAPT Therapeutics during the 4th quarter valued at $35,316,000. Finally, Los Angeles Capital Management LLC grew its stake in shares of RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock worth $348,000 after acquiring an additional 18,558 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of RAPT Therapeutics in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $4.00.

RAPT Therapeutics Trading Up 6.2%

Shares of RAPT Therapeutics stock traded up $0.05 on Monday, reaching $0.80. The stock had a trading volume of 278,528 shares, compared to its average volume of 855,108. RAPT Therapeutics, Inc. has a 1 year low of $0.75 and a 1 year high of $4.83. The company has a market cap of $105.61 million, a P/E ratio of -0.29 and a beta of -0.04. The business's 50 day moving average is $1.03 and its two-hundred day moving average is $1.25.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. On average, equities analysts anticipate that RAPT Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.